INCEPT-Albumin

Human albumin is used during the treatment of adults with shock in the intensive care unit (ICU), but at present it is uncertain if it improves patient-important outcomes. INCEPT-Albumin is an investigator-initiated, open-label domain with an integrated feasibility phase on INCEPT. The domain will assess the effects of albumin for resuscitation and substitution therapy versus no use of albumin on the number of days alive without life support at 30 days and other patient-important outcomes in adult ICU patients with shock.

The INCEPT-Albumin domain is partly funded by Danmarks Frie Forskningsfond.

Further details will be added here before recruitment begins.
The approved, the domain-specific appendix and a list of key persons and domain management committee members for INCEPT-Albumin are available under Documents.